Comparative Pharmacology
Head-to-head clinical analysis: COXANTO versus DYLOJECT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COXANTO versus DYLOJECT.
COXANTO vs DYLOJECT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of soluble epoxide hydrolase (sEH), increasing levels of epoxyeicosatrienoic acids (EETs), which have vasodilatory, anti-inflammatory, and antifibrotic effects.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
1 g intravenous every 6 hours.
50 mg intramuscularly every 6 hours as needed for pain; maximum 150 mg per day.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours (prolonged to 24-30 hours in moderate-to-severe renal impairment, requiring dose adjustment)
2-4 hours (terminal) in adults; prolonged in elderly (up to 6-8 hours) and hepatic impairment (up to 12 hours).
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Renal: ~50% as unchanged drug and metabolites (glucuronide conjugates); Biliary/fecal: ~40% as metabolites; <5% unchanged in feces.
Category C
Category C
NSAID
NSAID